Condition: Hypertension (HTN) · Sponsor: Sarfez Pharmaceuticals, Inc.
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
This description comes directly from the study's public registry record.
Salim Shah, PhD, JD · 877-872-7339 · info@sarfez.com
Sophia Shah, MD · 877-872-7339 · Sophia.Shah@sarfez.com
Always discuss trial participation with your own doctor first.
| Sarfez Pharmaceuticals, Inc. | Vienna, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223502